Travere Therapeutics, Inc. Common Stock

Travere Therapeutics trades at a market cap of $4.0B despite posting no positive earnings, suggesting the market is pricing in substantial future profitability from its pipeline. The 18.05% short interest combined with an RSI of 64.8 creates a notable tension: the stock approaches overbought momentum while a meaningful short position lingers, establishing potential squeeze dynamics if positive catalysts emerge. Trading below its 52-week high provides some caution against euphoria, yet the absence of earnings makes valuation entirely speculative—the risk/reward hinges entirely on whether development-stage assets deliver commercial success.